Overview
Epredia is a global provider of precision cancer diagnostics that supplies pathology products and technologies to help clinicians detect and understand cancer. Its offerings include reagents, instruments, slides, and related assays used by pathologists to examine tissue samples in anatomical pathology, enabling more precise cancer diagnoses. The company leverages a portfolio of trusted legacy brands—Shandon, Microm, Menzel Gläser, and Richard-Allan Scientific—and PHC Group backing to reach customers worldwide; 44 of its products are used in cancer care at any moment, and customers rely on its solutions more than a billion times each year. Compared with others in the market, Epredia combines long-standing brand legacies with corporate support from PHC Group to deliver a broad, globally adopted suite of pathology tools. Its goal is to improve patient outcomes by delivering high-quality diagnostic technologies that empower pathologists to make accurate, timely cancer assessments.
Work here?Claim your company
Simplify's take
What believers are saying
- July 28, 2026 BlockTracker and SlideTracker target sample traceability pain in labs.
- August 5, 2026 Leeds NHS partnership supports international adoption of AI-enabled pathology.
- The May 14, 2026 SlideMate Thermal printer expands traceability products for smaller labs.
What critics are saying
- Digital pathology sales depend on hospital capex cycles and skeptical pathologist adoption.
- Mindpeak integration across Epredia's E1000 Dx remains future tense, delaying software revenue.
- If Philips or Roche accelerate competing pathology stacks, Epredia becomes a hardware commodity.
What makes Epredia unique
- Epredia bundles slides, instruments, scanners, and software across the pathology workflow.
- Its May 7, 2026 E1000 Dx scans 1,500 samples daily with automated quality control.
- The February 24, 2026 Mindpeak deal adds AI recognition to Epredia's EU portfolio.
Help us improve and share your feedback! Did you find this helpful?